1
|
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaïd C, Guisier F. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study). Target Oncol 2023; 18:905-914. [PMID: 37966566 DOI: 10.1007/s11523-023-01014-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2023] [Indexed: 11/16/2023]
Abstract
BACKGROUND Although ALK-translocated (ALK+) advanced non-small cell lung cancers (aNSCLCs) are currently treated with second- or third-generation ALK inhibitors (ALK-TKIs), some patients respond durably to the first-generation ALK-TKI crizotinib. OBJECTIVE This study aimed to describe the clinical characteristics of these long-term responders. PATIENTS AND METHODS This national, multicenter, retrospective, non-interventional study included patients with ALK+ aNSCLCs and long-term responses to first (L1)- or subsequent (≥ L2)-line crizotinib, defined, respectively, as treatments lasting > 18 and > 10 months. Median treatment duration (mDOT) was the primary endpoint. RESULTS A total of 85 patients (32 L1 and 53 ≥ L2 responders) from 23 centers were included (receiving crizotinib between 10/24/2011-10/02/2018): median age of 59 years, 83.6% non-smokers or ex-smokers, 85.9% performance status (PS) 0/1, 94.1% with adenocarcinomas, median of one metastatic site, and 22.4% with brain metastases (BMs). After median follow-up of 73.4 [95% confidence interval, 67.5-79.9] months, respective L1 and ≥ L2 mDOTs were 43.3 [26.7-56.8] and 29.6 [22.6-35.8] months, with overall survival (OS) not reached (NR) and 116.2 [83.4-NR] months. BM presence or absence did not affect mDOT (31.4 versus 32.9 months) but significantly impacted median OS (70.6 versus 158.6 months; p = 0.0008). Progression on crizotinib was paucisymptomatic (74.1%) and oligometastatic (34.8%), especially BMs (42.4%). After crizotinib discontinuation, 65 (76.5%) patients received subsequent systemic therapy: 57 (67.1%) with second-generation ALK-TKIs. Respective mDOTs of first- and second-line post-crizotinib ALK-TKIs lasted 19.4 [14.9-25.6] and 11.1 [4.8-17.9] months, respectively. CONCLUSIONS Most ALK+ aNSCLC patients with prolonged crizotinib efficacy had paucisymptomatic and oligometastatic disease without BMs. They subsequently benefited from a sequential strategy with other ALK-TKIs.
Collapse
Affiliation(s)
| | - Renaud Descourt
- Institut de Cancérologie, Hôpital Morvan, CHU de Brest, Brest, France
| | | | - Hélène Doubre
- Service d'Oncologie Thoracique, Hôpital Foch, Suresnes, France
| | | | | | | | - Lionel Falchero
- Service de Pneumologie, Hôpital Nord-Ouest de Villefranche-sur-Saône, Gleizé, France
| | - Eric Huchot
- Service de Pneumologie, CHU Saint-Pierre, La Réunion, France
| | - Sabine Vieillot
- Service d'Oncologie, Clinique Saint Pierre, Perpignan, France
| | - Romain Corre
- Service de Pneumologie, CH Quimper, Quimper, France
| | - Laure Kazulinski
- Service de Pneumologie, CH du Cotentin Cherbourg, Cherbourg, France
| | - Acya Bizieux
- Service de Pneumologie, CH La Roche-sur-Yon, La Roche-sur-Yon, France
| | | | - Hugues Morel
- Service de Pneumologie, CH Orléans, Orléans, France
| | | | - Christos Chouaïd
- Service de Pneumologie, Centre Hospitalier Intercommunal, Créteil, France
| | | |
Collapse
|
2
|
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, Lemiale V. Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24]. Bull Cancer 2023; 110:467-468. [PMID: 36805208 DOI: 10.1016/j.bulcan.2023.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- Anne-Pascale Meert
- Institut Jules-Bordet, université Libre de Bruxelles (ULB), service de médecine interne, soins intensifs et urgences oncologiques, Brussels, Belgium
| | | | - Muriel Picard
- Institut universitaire du cancer de Toulouse-Oncopole, CHU de Toulouse, Intensive Care Unit, Toulouse, France
| | - Paul Jaubert
- AP-HP Cochin, Intensive care unit, Paris, France
| | | | - Philippe Bauer
- Mayo Clinic, Pulmonary and Critical Care Medicine, Rochester, MN, USA
| | - Djamel Mokart
- Institut Paoli-Calmette, réanimation polyvalente et département d'anesthésie et de réanimation, Marseille, France
| | - Andry Van De Louw
- Pennsylvania State University, Division of Pulmonary and Critical Care, Hershey, PA, USA
| | - Stefan Hatzl
- Medical University of Graz, Department of Internal Medicine, Graz, Austria
| | | | | | | | - Luca Montini
- Intensive Care Unit, Department of Intensive Care Medicine and Anesthesiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | | | | | - Amelie Seguin
- Hôtel Dieu-HME, University Hospital of Nantes, Medical Intensive Care Unit, Nantes, France
| | - Pleun Hemelaar
- Radboud University Medical Center, Department of Intensive Care Medicine, Nijmegen, The Netherlands
| | - Elie Azoulay
- AP-HP Saint-Louis, Intensive Care Unit, Paris, France
| | | |
Collapse
|
3
|
Akli A, Girard N, Fallet V, Rousseau-Bussac G, Gounant V, Friard S, Trédaniel J, Dujon C, Wislez M, Duchemann B, Giroux-Leprieur E. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study. Target Oncol 2022; 17:675-682. [PMID: 36129569 DOI: 10.1007/s11523-022-00915-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/26/2022] [Indexed: 11/24/2022]
Abstract
BACKGROUND Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in first line for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). OBJECTIVE The identification of related histomolecular resistance mechanisms to first-line osimertinib is a critical step to define the optimal treatment strategy beyond progression. PATIENTS AND METHODS All consecutive patients treated in the first line with osimertinib for advanced EGFR-mutated NSCLC at 10 hospitals in the Greater Paris area between April 2015 and January 2021 were included. Histomolecular data from plasma and tissue samples taken at progression under osimertinib were collected, and all samples were analyzed using DNA next-generation sequencing. Data on objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to treatment discontinuation (TTD) were also collected. RESULTS Overall, 104 patients were included. Most patients had adenocarcinoma (n = 102, 98%) with an exon 19 EGFR deletion (n = 54, 52%). Forty-two patients (50%) had central nervous system (CNS) metastasis at the time of osimertinib initiation. ORR was 76%, median PFS and OS were 12.6 months and 52 months, respectively, and TTD was 33 months. At the time of analysis, 44 patients (42%) had tumor progression, and among these patients, 27 (61%) contributive samples were available. The most frequent molecular alterations at progression were mesenchymal epithelial transition factor (MET) amplification (15%; n = 4) and EGFR C797S mutation (11%; n = 3). Histological transformation was found in one patient (4%). RNA next-generation sequencing was performed in eight patients and showed a CCDC6-RET fusion in one patient (12%). CONCLUSIONS We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation-positive NSCLC. At progression, the most frequent histomolecular alterations were MET amplification and EGFR C797S mutation.
Collapse
Affiliation(s)
- Assya Akli
- Department of Respiratory Diseases and Thoracic Oncology, APHP-Hopital Ambroise Pare, Paris-Saclay University, UVSQ, 9 avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France
| | - Nicolas Girard
- Institute Curie, Thorax Institute, Paris-Saclay University, UVSQ, Paris, France
| | - Vincent Fallet
- Department of Pneumology and Thoracic Oncology, APHP-Hopital Tenon, Sorbonne University, Paris, France
| | | | - Valérie Gounant
- Thoracic Oncology Department, Paris-Cité University, APHP-Hopital Bichat, Paris, France
| | - Sylvie Friard
- Pneumology Department, Foch Hospital, Suresnes, France
| | - Jean Trédaniel
- Pneumology Department, Saint-Joseph Hospital, Paris, France
| | - Cécile Dujon
- Pneumology Department, André Mignot Hospital, Le Chesnay, France
| | - Marie Wislez
- Department of Pulmonology, Thoracic Oncology Unit, APHP-Hopital Cochin, Paris-Cité University, Paris, France
| | - Boris Duchemann
- Department of Medical Oncology, APHP-Hopital Avicenne, Sorbonne Paris Nord University, Bobigny, France
| | - Etienne Giroux-Leprieur
- Department of Respiratory Diseases and Thoracic Oncology, APHP-Hopital Ambroise Pare, Paris-Saclay University, UVSQ, 9 avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France.
| |
Collapse
|
4
|
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, Lemiale V. When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study. Bull Cancer 2022; 109:916-924. [PMID: 35718570 DOI: 10.1016/j.bulcan.2022.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 04/17/2022] [Accepted: 04/20/2022] [Indexed: 11/25/2022]
Abstract
PURPOSE To study prevalence of targeted therapy (TT)-related adverse events requiring ICU admission in solid tumor patients. METHODS Retrospective multicenter study from the Nine-i research group. Adult patients who received TT for solid tumor within 3 months prior to ICU admission were included. Patients admitted for TT-related adverse event were compared to those admitted for other reasons. RESULTS In total, 140 patients, median age of 63 (52-69) years were included. Primary cancer site was mostly digestive (n=27, 19%), kidney (n=27, 19%), breast (n=24, 17%), and lung (n=20, 14%). Targeted therapy was anti-VEGF/VEGFR for 27% (n=38) patients, anti-EGFR for 22% (n=31) patients, anti-HER2 for 14% (n=20) patients and anti-BRAF for 9% (n=5) patients. ICU admission was related to TT adverse events for 30 (21%) patients. The most frequent complications were interstitial pneumonia (n=7), cardiac failure (n=5), anaphylaxis (n=4) and bleeding (n=4). At ICU admission, no significant difference was found between patients admitted for a TT-related adverse event and the other patients. One-month survival rate was higher in patients admitted for TT adverse event (OR=5.733 [2.031-16.182] P<0.001). CONCLUSIONS Adverse events related to targeted therapy accounted for 20% of ICU admission in our population and carried a 16% one-month mortality. Outcome was associated with admission for TT related to adverse event, breast cancer and good performance status.
Collapse
Affiliation(s)
- Anne-Pascale Meert
- Institut Jules-Bordet, université Libre de Bruxelles (ULB), service de médecine interne, soins intensifs et urgences oncologiques, Brussels, Belgium
| | | | - Muriel Picard
- Institut universitaire du cancer de Toulouse-Oncopole, CHU de Toulouse, Intensive Care Unit, Toulouse, France
| | - Paul Jaubert
- AP-HP Cochin, Intensive care unit, Paris, France
| | | | - Philippe Bauer
- Mayo Clinic, Pulmonary and Critical Care Medicine, Rochester, MN, USA
| | - Djamel Mokart
- Institut Paoli-Calmette, réanimation polyvalente et département d'anesthésie et de réanimation, Marseille, France
| | - Andry Van De Louw
- Pennsylvania State University, Division of Pulmonary and Critical Care, Hershey, PA, USA
| | - Stefan Hatzl
- Medical University of Graz, Department of Internal Medicine, Graz, Austria
| | | | | | | | - Luca Montini
- Intensive Care Unit, Department of Intensive Care Medicine and Anesthesiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | | | | | - Amelie Seguin
- Hôtel Dieu-HME, University Hospital of Nantes, Medical Intensive Care Unit, Nantes, France
| | - Pleun Hemelaar
- Radboud University Medical Center, Department of Intensive Care Medicine, Nijmegen, The Netherlands
| | - Elie Azoulay
- AP-HP Saint-Louis, Intensive Care Unit, Paris, France
| | | |
Collapse
|
5
|
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot A, Guisier F, Galland L, Do P, Schott R, Dansin E, Arrondeau J, Auliac J, Chouaid C. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1805] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Valery S, Chouaid C, Rousseau-Bussac G, Monnet I, Bilger G, Boré P, Pinsolle J, Descourt R, Geier M, Toffart A, Cony-Makhoul P, Robinet G, Ennahdi F, Zaccaria I, Decroisette C. Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors - AVATAX , a retrospective multicentric study: Preliminary data. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Mehlman C, Cadranel J, Lacave R, Rousseau-Bussac G, Pujals A, Girard N, Bieche I, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer. Lung Cancer 2019. [DOI: 10.1183/13993003.congress-2019.pa370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. Lung Cancer 2019; 137:149-156. [PMID: 31600593 DOI: 10.1016/j.lungcan.2019.09.019] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 09/24/2019] [Accepted: 09/25/2019] [Indexed: 10/25/2022]
Abstract
OBJECTIVES The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC). MATERIALS AND METHODS We performed a multicentric retrospective analysis on a cohort of consecutive patients treated with osimertinib for an advanced EGFR-mutated NSCLC and collected histo-molecular data from plasma and tumor samples at the time of progression. Next-generation sequencing (NGS) was performed for all samples. Best Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and data on treatment post-progression efficacy were also collected. RESULTS Two-hundred and twenty-six patients were included from 9 Academic French Hospitals between April 2015-October 2018. Osimertinib was given in second-line or more in 219 patients (97%). Best ORR was 52% and best central nervous system ORR was 56%. Median PFS and OS were 9.5 months (IQR 4.0-17.2) and 24 months (IQR 12.4-NR) respectively. At the time of analysis, 150 patients (66%) had tumor progression. Among them, 73 contributive samples (56 tumor biopsies) were available. The most frequent molecular alterations were C797S mutation (n = 9 (13%)) and MET amplification (n = 8 (11%)). Histologic transformation occurred in 5 patients (9% of tumor biopsies). In T790M + NSCLC, loss of T790 M occurred in 68% of cases. Median PFS and OS with treatment beyond progression were 6.0 months (IQR 2.0-10.4) and 15.1 months (IQR 6.7-NR) respectively and longer in case of osimertinib continuation beyond progression. CONCLUSION We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation positive NSCLC. At progression, the most frequent molecular alterations were MET amplification and C797S mutation.
Collapse
Affiliation(s)
- Camille Mehlman
- Department of Respiratory Diseases and Thoracic Oncology, APHP - Hopital Ambroise Pare, EA 4340 BECCOH, UVSQ, Paris Saclay University, Boulogne-Billancourt, France
| | - Jacques Cadranel
- Chest Department-Thoracic Oncology Expert Center, AP-HP, Groupe Hospitalier HUEP, Hopital Tenon, Paris, France, and Sorbonne University, Paris, France
| | | | - Roger Lacave
- Department of Solide Tumours Genetic, AP-HP, Groupe Hospitalier HUEP, Tenon Hospital, Paris, France, and Sorbonne University, Paris, France
| | - Anaïs Pujals
- Department of Pathology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Nicolas Girard
- Thorax Institute, Institute Curie and PSL University, Paris, France
| | | | - Valérie Gounant
- Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Nathalie Théou-Anton
- Genetics Department, University Hospital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Sylvie Friard
- Pneumology Department, Foch Hospital, Suresnes, France
| | - Jean Trédaniel
- Pneumology Department, Saint-Joseph Hospital, Paris, France
| | - Hélène Blons
- Molecular Biology Department, Georges Pompidou European Hospital, AP- HP, Paris, France and INSERM UMR-S1147, CNRS SNC 5014, Saints-Pères Research Center, Paris-Descartes University, Sorbonne Paris Cité University, Paris, France
| | - Cécile Dujon
- Pneumology Department, André Mignot Hospital, Le Chesnay, France
| | - Boris Duchemann
- Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France and Paris XIII University, Sorbonne Paris Cité, Paris, France and Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy Cancer Campus, Villejuif, France
| | - Pierre Olivier Schischmanoff
- Department of Molecular Oncogenetics, Avicenne Hospital, AP-HP, Bobigny, France and INSERM UMR U978/Paris XIII University, Sorbonne Paris Cité University, Paris, France
| | - Thierry Chinet
- Department of Respiratory Diseases and Thoracic Oncology, APHP - Hopital Ambroise Pare, EA 4340 BECCOH, UVSQ, Paris Saclay University, Boulogne-Billancourt, France
| | - Etienne Giroux Leprieur
- Department of Respiratory Diseases and Thoracic Oncology, APHP - Hopital Ambroise Pare, EA 4340 BECCOH, UVSQ, Paris Saclay University, Boulogne-Billancourt, France.
| |
Collapse
|
9
|
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot AB, Guisier F, Gervais R, Galland L, Schott R, Dansin E, ARRONDEAU J, Auliac JB, Chouaid C. Brigatinib in pretreated patients with ALK-positive advanced NSCLC. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.9045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9045 Background: Brigatinib is a next-generation ALK inhibitor initially developed in pre-treated ALK+ NSCLC. Data on the efficacy of brigatinib in real world remain rare. Methods: This retrospective multicentric study analyzed ALK-+ advanced NSCLC patients pretreated with at least two tyrosine-kinase inhibitors, including crizotinib, and enrolled in the brigatinib French early access program. The primary endpoint was investigator-assessed progression-free survival (PFS). Results: 104 patients were included (mean age, 56.6 years; never smokers, 61.5%; adenocarcinoma, 98.1%). Patients had received a median of 3 previous treatment lines, including at least 2 ALK inhibitors, mainly crizotinib then ceritinib in 93% patients. At brigatinib initiation, 59.1% had performance status 0-1, 51.9% had ≥ 3 metastatic sites, 74.5% had central nervous system metastases (CNS) and 8.8% had carcinomatous meningitis. Median duration of brigatinib treatment was 6.7 (0.06–20.7) months. Median PFS was 6.6 (95% CI, 4.8–9.9) months for the entire population. In the 91 evaluable patients, disease control rate was 78.2% (stable, 28.2%; partial response, 45.7%; complete response, 4.3%). From brigatinib start, median overall survival was 17.2 (95% CI:11.0–not reached) months. Among the 68 patients with progressive disease after brigatinib, CNS was involved in 29.4% of cases. Ten (9.6%) patients had treatment discontinuation due to intolerance or patient request. Median OS from the diagnostic of NSCLC was 75,3 (95% CI, 38,2-174,6) months. Conclusions: This study confirms the efficacy of brigatinib in a cohort of patients heavily pretreated for ALK-+advanced NSCLC. These real-world results are consistent with clinical data reported in clinical trials.
Collapse
Affiliation(s)
| | - Maurice Perol
- Department of Thoracic Oncology, Centre Léon Bérard, Lyon, France
| | | | - David Planchard
- Medical Oncology Department, Thoracic Group, Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Assie J, Monnet I, Rousseau-Bussac G, Jabot L, Vinas F, Mejri I, Gibiot Q, Boudjemaa A, Chouaid C. Longs survivants après immunothérapie pour cancer du poumon non à petites cellules métastatiques : prévalence, caractéristiques cliniques et modalités de prise en charge. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Mejri I, Boudjemaa A, Viñas F, Gibiot Q, Rousseau-Bussac G, Maître B, Housset B, Mangiapan G. Amélioration de la prise en charge par l’évaluation des pratiques : exemple de la mise en place de la sédation vigile dans une unité d’endoscopie bronchique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Gervais R, Dansin E, Schott R, Arrondeau J, Dujon C, Madelaine J, Jeannin G, Bylicki O, Daniel C, Spaeth D, Auliac J, Chouaïd C. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petites cellules avec translocation ALK en France. Étude BRIGALK. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Boudjemaa A, Rousseau-Bussac G, Monnet I. Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab. J Thorac Oncol 2018; 13:e39-e40. [DOI: 10.1016/j.jtho.2017.10.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 10/14/2017] [Accepted: 10/14/2017] [Indexed: 10/18/2022]
|
14
|
Thibault De Menonville C, De Torcy M, Gibiot Q, Vinas F, Rousseau-Bussac G, Jabot L, Monnet I, Chouaid C. Patients avec cancer bronchopulmonaire sous immunothérapie : intérêt du Pet Scanner. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Mangiapan G, Boudjemaa A, Viñas F, Gibiot Q, Benhassen I, Rousseau-Bussac G, Lasseur M, Housset B. Différence entre la mesure échographique et l’épaisseur réelle de la paroi thoracique. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Lasseur M, Boudjemaa A, Viñas F, Gibiot Q, Benhassen I, Rousseau-Bussac G, Housset B, Mangiapan G. Évaluation du contrôle de la douleur induite par les actes pleuraux. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Gendarme S, De Torcy M, Gibiot Q, Ben Assem I, Vinas F, Boudjemaa A, Rousseau-Bussac G, Monnet I, Chouaid C. Prise en charge des cancers bronchopulmonaires non métastatiques avec mutations oncogéniques : quelle place pour les traitements ciblés ? Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Caliez J, Monnet I, Pujals A, Rousseau-Bussac G, Jabot L, Boudjemaa A, Leroy K, Chouaid C. Adénocarcinome bronchique avec mutation de l’ EGFR et réarrangement ALK concomitants. Rev Mal Respir 2017; 34:576-580. [DOI: 10.1016/j.rmr.2016.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 07/11/2016] [Indexed: 12/09/2022]
|
19
|
Elvarathnam S, Chouaid C, Thiriat. N, Jabot L, Rousseau-Bussac G, Jaskowiec C, Vinas F, Poullain S, Monnet I. P3.02c-089 ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Selvaratnam S, Chouaid C, Thiriat N, Jabot L, Rousseau-Bussac G, Jaskowiec C, Vinas F, Poullain S, Monnet I. Étude prospective d’une cohorte de patients, atteints de cancer bronchique non à petites cellules, traités par une monothérapie de nivolumab en pratique clinique courante. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Gauvain C, Crequit P, Rousseau-Bussac G, Ganoun A, Baud M, Chouaid C. [Adjuvant chemotherapy of non-small cell lung cancer: Tolerance of combined cisplatin-pemetrexed therapy]. Rev Mal Respir 2014; 31:817-21. [PMID: 25433586 DOI: 10.1016/j.rmr.2013.10.646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2013] [Accepted: 10/22/2013] [Indexed: 11/25/2022]
Abstract
RATIONALE Adjuvant chemotherapy is standard for non-small cell lung cancer (NSCLC) after surgical resection. In this context, the tolerance of the treatment is an essential criterion in the choice of chemotherapy. This exploratory study evaluated, in the situation of adjuvant chemotherapy, the tolerance of combined cisplatin-pemetrexed. The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. RESULTS The analysis included 23 patients (age: 58.7 ± 5 years, men: 56%, average creatinin clearance (Clea): 94 ± 22 mL/min, average haemoglobin: 13.8 ± 1.6g/dL). Over 92 planned courses, 7.6% are postponed (neutropenia), 4.3% were not given (asthenia). We noted 7 episodes of vomiting (4 grade 3), with two hospitalizations in the same patient; 5 episodes of anaemia grade 1-2 not requiring EPO prescription or transfusion and no febrile neutropenia. At the end of the treatment, three patients had a Clea<50 mL/mn and 5 a haemoglobin between 9 and 11 g/dL. CONCLUSION Combined cisplatin-pemetrexed in an adjuvant situation has a satisfactory tolerance.
Collapse
Affiliation(s)
- C Gauvain
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - P Crequit
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - G Rousseau-Bussac
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - A Ganoun
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - M Baud
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France
| | - C Chouaid
- Service de pneumologie, hôpital Saint-Antoine, AP-HP, 75012 Paris, France; Service de pneumologie, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
| |
Collapse
|
22
|
Rousseau-Bussac G, Crequit P, Alifano M, Chouaid C. [Management of malignant pericardial effusion in lung cancer]. Rev Mal Respir 2014; 31:746-53. [PMID: 25391509 DOI: 10.1016/j.rmr.2014.02.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Accepted: 02/06/2014] [Indexed: 01/19/2023]
Abstract
Acute pericarditis associated with lung cancer is a relatively frequent complication but is usually not symptomatic unless it causes tamponade. The clinical presentation is classically with dyspnea, thoracic pain, signs of right cardiac failure then left cardiac failure and syncope but it is often a difficult diagnosis in a patient with multi-symptomatic disease. The diagnosis is based on cardiac echography. Toxicity due to radiotherapy or more rarely an infectious etiology must be considered. Clinically significant effusions must be drained because of the high rate of recurrence after a simple aspiration. Drainage is formally indicated when, at echocardiography, the effusion exceeds 20mm in diastole, in cases of tamponade or in cases of compromised hemodynamic status. The formation of a pericardial window at thoracotomy prevents recurrences. Based on old, retrospective, very heterogeneous case series the prognosis, is generally considered to be poor with a median survival which does not exceed 100 days and a one year survival generally lower than 10%. Prognosis is better where diagnosis occurs at an earlier stage allowing regular follow-up and surgical intervention in a non-emergency setting.
Collapse
Affiliation(s)
| | - P Crequit
- Service de pneumologie, hôpital Saint-Antoine, Paris, France
| | - M Alifano
- Service de chirurgie thoracique, hôpital Cochin, Paris, France
| | - C Chouaid
- Service de pneumologie, hôpital Saint-Antoine, Paris, France; Service de pneumologie et de pathologie professionnelle, CHI de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
| |
Collapse
|
23
|
Lavolé A, Lejeune C, Epaud C, Rosencher L, Ruppert AM, Gounant V, Créquit P, Rousseau-Bussac G, Wislez M, Cadranel J. Délai de prise en charge du cancer du poumon (CP) en hôpital de jour d’un centre expert en oncologie thoracique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Gauwin C, Crequit P, Rousseau-Bussac G, Ganoun A, Baud M, Chouaid C. Traitement adjuvant des cancers bronchiques non à petites cellules : tolérance de l’association platine–pemetrexed. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Sese L, Didier M, Rousseau-Bussac G, Crequit P, Masanes MJ, Chouaid C. Chimiothérapies en fin de vie chez les patients pris en charge pour cancers pulmonaires : analyse des pratiques. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Rousseau-Bussac G, Strano S, Phin-Huynh S, Regnard JF, Alifano M, Chouaid C. Pronostic des péricardites chez les patients pris en charge pour cancer du poumon. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
27
|
Rousseau-Bussac G, Margetis D, Lino A, Galbois A, Phin-Huynh S, Maury E, Chouaid C. Pronostic des patients atteints de cancer du poumon pris en charge en réanimation médicale. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Rousseau-Bussac G, Dixmier A, Papanikolaou I, Baud M, Lebeau B, Chouaid C. 191 Évolution des patients transférés en réanimation dans le cadre de la prise en charge d’un cancer bronchopulmonaire. Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)72567-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|